Changes in Eosinophil Cationic Protein and Sputum Eosinophils Following Allergen Immunotherapy (NCT07694947) | Clinical Trial Compass
CompletedNot Applicable
Changes in Eosinophil Cationic Protein and Sputum Eosinophils Following Allergen Immunotherapy
Egypt100 participantsStarted 2023-01-01
Plain-language summary
Asthma is a chronic heterogeneous inflammatory airway disease affecting millions worldwide and remains a major global health burden. Despite advances in pharmacological therapy, a substantial proportion of patients continue to experience uncontrolled symptoms due to persistent airway inflammation and disease heterogeneity.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age above 18 years and diagnosed of allergic asthma. Patients were clinical stabile and confirmed diagnosis supported by pulmonary function test.
Exclusion Criteria:
* pregnant
* parasitic infestations
* recent acute asthma exacerbation
* current smoking
* severe persistent asthma
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial looked at changes in eosinophil cationic protein and sputum eosinophils after allergen immunotherapy — can you explain what those markers tell us about my allergic asthma and whether testing them would be useful in my own care?
2Since this trial is listed as Phase NA and has already been completed, what do its findings actually show about how allergen immunotherapy affects airway inflammation, and does that evidence apply to someone with my specific situation?
3The trial measured 'clinical response' as its main outcome — what counts as a meaningful clinical response in allergic asthma treatment, and how would we know if immunotherapy was working for me in that way?
4Given that this study focused on allergen immunotherapy, how does that approach compare to the standard medications I might already be taking for allergic asthma, and would it make sense to try those first or alongside immunotherapy?
5Are my own eosinophil levels or any sputum test results something you'd want to check before deciding whether allergen immunotherapy is a reasonable path for me to consider?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.